Construction Of Immune-related LncRNA Pairs Model And Prognosis Analysis Of Clear Cell Renal Cell Carcinoma Based On Bioinformatics

Objective:The incidence of clear cell Renal cell Carcinoma(ccRCC)is increasing in China,and LncRNA is an important regulatory factor in human body.Therefore,this study screened immune-related LncRNA pairs through bioinformatics analysis,and constructed a new model which predict the clinical outcome and immunotherapeutic response.Methods:1.In this study,bioinformatics analysis techniques and other data analysis tools were used to extract gene expression profile data from KIRC database on TCGA website and a series of identified immune-related genes(IR-genes)were obtained from ImmPort database,and irlncRNAs(immune-related lncRNAs)were screened by co-expression strategy.Correlation analysis was conducted between immune-related genes and all lncrnas.2.Combined with the clinical survival status and survival time data of TCGA,26 pairs of prognostic DEirlncRNA were obtained by univariate Cox regression analysis and Lasso regression analysis,and 10 pairs of independent prognostic DEirlncRNA were determined by multivariate Cox regression analysis.3.By calculating the Area under curve(AUC),the Akaike information Standard(AIC)value of the subject characteristic curve was estimated,and the cut-off point was determined,and the risk model was established.4.The risk model was constructed to divide patients with ccRcc into high and low disease risk groups.The risk model was evaluated from the perspectives of survival rate,clinicopathological characteristics of patients,infiltrating immune cells in tumors,efficacy of targeted drugs,and immunoregulatory biomarkers.Conclusions:The model established by DEirlncRNA pairs can perform well at different levels of IncRNA expression,and predict patients who can benefit from immunotherapy and targeted therapy.In this study,the model established by DEirlncRNA was used to screen out sensitive targeted drugs such as immune checkpoint PD-1 inhibitor,which also provided new ideas for immunological research and clinical treatment of ccRCC patients.